Biohit Oyj’s Financial Reporting and Annual General Meeting in 2023

Publishing on November 30, 2022 at 2:00 pm local time (EEST)

Biohit Oyj will release its financial statements for 2022 on Wednesday February 15th, 2023, at 9:30 am.

The Annual report, which contains the Financial Statement for 2022 and the Report of the Board of Directors, will be published on Wednesday March 22nd, 2023, at 9:30 am.

Biohit Oyj’s Annual General Meeting has been planned for Wednesday 14th of June 2023 at 2:00 pm. The Board of Directors will call the General meeting at a later date.

Half year financial report for period January-June (H1) 2023 will be published on Wednesday 9th of August, 2023, at 9:30 am.

The published economic reports and other stock exchange releases are available on Biohit's website at www.biohithealthcare.com/investors. The website also contains an online form for ordering electronic copies, which will be e-mailed to you, available at http://www.biohithealthcare.com/investors/stock-exchange-releases/order-releases-to-your-email.

Additional information: 
Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50 383 5948

investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com